Jia Zhu1,2, Xingshun Qi1, Haonan Yu2, Eric M Yoshida3, Nahum Mendez-Sanchez4, Xintong Zhang1, Ran Wang1, Han Deng1, Jing Li1, Dan Han1, Xiaozhong Guo1. 1. Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang, China. 2. Postgraduate College, Shenyang Pharmaceutical University, Shenyang, China. 3. Division of Gastroenterology, Vancouver General Hospital, Vancouver, Canada. 4. Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico.
Abstract
BACKGROUND: Hepatic encephalopathy is associated with altered gut microbiota. Proton pump inhibitors increase the risk of small bowel bacterial overgrowth. OBJECTIVES: This was a case-control study aimed at exploring the relationship of proton pump inhibitor use with the risk of hepatic encephalopathy during hospitalization in liver cirrhosis. METHODS: Case and control groups were defined as cirrhotic patients who developed hepatic encephalopathy during hospitalization and those without hepatic encephalopathy at admission or during hospitalization, respectively. Age, gender, and Child-Pugh score were matched between the groups. Odds ratios with 95% confidence intervals were calculated to express the association of proton pump inhibitors with the risk of hepatic encephalopathy. Four subgroup analyses were performed after excluding patients with acute upper gastrointestinal bleeding, infections, and in-hospital death, and after matching model for end-stage liver disease score. RESULTS: In the overall analysis, 128 patients were included in each group of cases and controls. The proportion of proton pump inhibitor use was significantly higher in the case group than the control group (79.7% vs 43%, p < 0.001). Proton pump inhibitor use (odds ratio = 3.481, 95% confidence interval: 1.651-7.340, p = 0.001) was independently associated with the development of hepatic encephalopathy in the multivariate analysis. In the four subgroup analyses, proton pump inhibitor use remained independently associated with the risk of hepatic encephalopathy. CONCLUSION: Proton pump inhibitor use might increase the risk of hepatic encephalopathy during hospitalization.
BACKGROUND: Hepatic encephalopathy is associated with altered gut microbiota. Proton pump inhibitors increase the risk of small bowel bacterial overgrowth. OBJECTIVES: This was a case-control study aimed at exploring the relationship of proton pump inhibitor use with the risk of hepatic encephalopathy during hospitalization in liver cirrhosis. METHODS: Case and control groups were defined as cirrhotic patients who developed hepatic encephalopathy during hospitalization and those without hepatic encephalopathy at admission or during hospitalization, respectively. Age, gender, and Child-Pugh score were matched between the groups. Odds ratios with 95% confidence intervals were calculated to express the association of proton pump inhibitors with the risk of hepatic encephalopathy. Four subgroup analyses were performed after excluding patients with acute upper gastrointestinal bleeding, infections, and in-hospital death, and after matching model for end-stage liver disease score. RESULTS: In the overall analysis, 128 patients were included in each group of cases and controls. The proportion of proton pump inhibitor use was significantly higher in the case group than the control group (79.7% vs 43%, p < 0.001). Proton pump inhibitor use (odds ratio = 3.481, 95% confidence interval: 1.651-7.340, p = 0.001) was independently associated with the development of hepatic encephalopathy in the multivariate analysis. In the four subgroup analyses, proton pump inhibitor use remained independently associated with the risk of hepatic encephalopathy. CONCLUSION: Proton pump inhibitor use might increase the risk of hepatic encephalopathy during hospitalization.
Authors: Lotte G van Vlerken; Ellen J Huisman; Bart van Hoek; Willem Renooij; Felix W M de Rooij; Peter D Siersema; Karel J van Erpecum Journal: Eur J Clin Invest Date: 2012-01-31 Impact factor: 4.686
Authors: Hendrik Vilstrup; Piero Amodio; Jasmohan Bajaj; Juan Cordoba; Peter Ferenci; Kevin D Mullen; Karin Weissenborn; Philip Wong Journal: Hepatology Date: 2014-07-08 Impact factor: 17.425
Authors: Sherzad Balata; Steven W M Olde Damink; Karen Ferguson; Ian Marshall; Peter C Hayes; Nicolaas E p Deutz; Roger Williams; Joanna Wardlaw; Rajiv Jalan Journal: Hepatology Date: 2003-04 Impact factor: 17.425
Authors: Jasmohan S Bajaj; Douglas M Heuman; Phillip B Hylemon; Arun J Sanyal; Melanie B White; Pamela Monteith; Nicole A Noble; Ariel B Unser; Kalyani Daita; Andmorgan R Fisher; Masoumeh Sikaroodi; Patrick M Gillevet Journal: J Hepatol Date: 2013-12-25 Impact factor: 25.083
Authors: Seong Jun Hwang; Dong Hyeon Lee; Seong-Joon Koh; Ji Won Kim; Hyun Sun Park; Byeong Gwan Kim; Kook Lae Lee Journal: Turk J Gastroenterol Date: 2022-01 Impact factor: 1.555